Swiss exchange wants to entice biotech companies
This article was originally published in Clinica
Executive Summary
The Swiss stock exchange wants biotechnology companies to launch their IPOs on its market. The "New Market" in Zurich notes that US diagnostics and device flotations have not attracted the same numbers of subscribers that have flocked to Internet share offerings and argues that biotech IPO's in Switzerland could draw on the fact that Switzerland has traditionally been home to pharmaceutical companies.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.